Cargando…

A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity

BACKGROUND: The Single-Point Insulin Sensitivity Estimator (SPISE) is a biomarker of insulin sensitivity estimated using BMI and triglycerides and high-density lipoprotein cholesterol. We assessed the accuracy of SPISE to screen obesity-related cardiometabolic risk in children and adolescents. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Correa-Burrows, Paulina, Matamoros, Mariela, de Toro, Valeria, Zepeda, Diego, Arriaza, Marta, Burrows, Raquel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945119/
https://www.ncbi.nlm.nih.gov/pubmed/36843603
http://dx.doi.org/10.3389/fendo.2023.1078949
_version_ 1784892070954008576
author Correa-Burrows, Paulina
Matamoros, Mariela
de Toro, Valeria
Zepeda, Diego
Arriaza, Marta
Burrows, Raquel
author_facet Correa-Burrows, Paulina
Matamoros, Mariela
de Toro, Valeria
Zepeda, Diego
Arriaza, Marta
Burrows, Raquel
author_sort Correa-Burrows, Paulina
collection PubMed
description BACKGROUND: The Single-Point Insulin Sensitivity Estimator (SPISE) is a biomarker of insulin sensitivity estimated using BMI and triglycerides and high-density lipoprotein cholesterol. We assessed the accuracy of SPISE to screen obesity-related cardiometabolic risk in children and adolescents. METHOD: Cross-sectional validation study for a screening test in a sample of n=725 children and adolescents from an obesity clinic. Weight, height, waist circumference, blood arterial pressure, lipid profile, glucose, insulin and Tanner stage were measured. BMI, BMI for-age-and sex (BAZ), and HOMA-IR were estimated. HOMA-IR values ≥2.1 and ≥3.3 were considered IR in Tanner I-II, ≥3.3 for Tanner III-IV and ≥2.6 for Tanner V, respectively. Metabolic Syndrome (MetS) was diagnosed with the Cook phenotype. SPISE was estimated according to the following algorithm: [600* HDL^0.185/(TG^0.2* BMI^1.338)]. The optimal SPISE cut points for IR and MetS prediction were determined by ROC curve analysis. RESULTS: In prepubertal obese patients (9.2 ± 2.1y; 18.4% males), the prevalence of IR and MetS was 28.2% y 46.9%, respectively; 58% had severe obesity (BAZ ≥4 SD). In pubertal obese patients (12.6 ± 1.8y; 57% males), the prevalence of IR and MetS was 34.1% and 55.3%, respectively; 34% had severe obesity. In prepubertal children, a SPISE of 6.3 showed the highest sensitivity (73.2%) and specificity (80%) to screen individuals with IR (AUC: 0.80; LR +: 3.3). Likewise, a SPISE of 5.7 got the highest sensitivity (82.6%) and specificity (86.1%) to screen patients with MetS (AUC: 0.87; LR +: 5.4). In pubertal patients, a SPISE of 5.4 showed the highest sensitivity and specificity to screen children and adolescents with both IR (Sn: 76.1%; Sp: 77.5%; AUC: 0.8; LR +: 3.1) and MetS (Sn: 90.4%; Sp: 76.1%; AUC: 0.90; LR +: 3.5). CONCLUSION: In children and adolescents with obesity, SPISE has good or very good performance in predicting IR and MetS. SPISE may be considered a relatively simple and low-cost diagnosis tool that can be helpful to identify patients with greater biological risk. In adolescents with obesity, the same cut point allows identification of those at higher risk of both IR and MetS.
format Online
Article
Text
id pubmed-9945119
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99451192023-02-23 A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity Correa-Burrows, Paulina Matamoros, Mariela de Toro, Valeria Zepeda, Diego Arriaza, Marta Burrows, Raquel Front Endocrinol (Lausanne) Endocrinology BACKGROUND: The Single-Point Insulin Sensitivity Estimator (SPISE) is a biomarker of insulin sensitivity estimated using BMI and triglycerides and high-density lipoprotein cholesterol. We assessed the accuracy of SPISE to screen obesity-related cardiometabolic risk in children and adolescents. METHOD: Cross-sectional validation study for a screening test in a sample of n=725 children and adolescents from an obesity clinic. Weight, height, waist circumference, blood arterial pressure, lipid profile, glucose, insulin and Tanner stage were measured. BMI, BMI for-age-and sex (BAZ), and HOMA-IR were estimated. HOMA-IR values ≥2.1 and ≥3.3 were considered IR in Tanner I-II, ≥3.3 for Tanner III-IV and ≥2.6 for Tanner V, respectively. Metabolic Syndrome (MetS) was diagnosed with the Cook phenotype. SPISE was estimated according to the following algorithm: [600* HDL^0.185/(TG^0.2* BMI^1.338)]. The optimal SPISE cut points for IR and MetS prediction were determined by ROC curve analysis. RESULTS: In prepubertal obese patients (9.2 ± 2.1y; 18.4% males), the prevalence of IR and MetS was 28.2% y 46.9%, respectively; 58% had severe obesity (BAZ ≥4 SD). In pubertal obese patients (12.6 ± 1.8y; 57% males), the prevalence of IR and MetS was 34.1% and 55.3%, respectively; 34% had severe obesity. In prepubertal children, a SPISE of 6.3 showed the highest sensitivity (73.2%) and specificity (80%) to screen individuals with IR (AUC: 0.80; LR +: 3.3). Likewise, a SPISE of 5.7 got the highest sensitivity (82.6%) and specificity (86.1%) to screen patients with MetS (AUC: 0.87; LR +: 5.4). In pubertal patients, a SPISE of 5.4 showed the highest sensitivity and specificity to screen children and adolescents with both IR (Sn: 76.1%; Sp: 77.5%; AUC: 0.8; LR +: 3.1) and MetS (Sn: 90.4%; Sp: 76.1%; AUC: 0.90; LR +: 3.5). CONCLUSION: In children and adolescents with obesity, SPISE has good or very good performance in predicting IR and MetS. SPISE may be considered a relatively simple and low-cost diagnosis tool that can be helpful to identify patients with greater biological risk. In adolescents with obesity, the same cut point allows identification of those at higher risk of both IR and MetS. Frontiers Media S.A. 2023-02-08 /pmc/articles/PMC9945119/ /pubmed/36843603 http://dx.doi.org/10.3389/fendo.2023.1078949 Text en Copyright © 2023 Correa-Burrows, Matamoros, de Toro, Zepeda, Arriaza and Burrows https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Correa-Burrows, Paulina
Matamoros, Mariela
de Toro, Valeria
Zepeda, Diego
Arriaza, Marta
Burrows, Raquel
A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity
title A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity
title_full A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity
title_fullStr A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity
title_full_unstemmed A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity
title_short A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity
title_sort single-point insulin sensitivity estimator (spise) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945119/
https://www.ncbi.nlm.nih.gov/pubmed/36843603
http://dx.doi.org/10.3389/fendo.2023.1078949
work_keys_str_mv AT correaburrowspaulina asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity
AT matamorosmariela asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity
AT detorovaleria asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity
AT zepedadiego asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity
AT arriazamarta asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity
AT burrowsraquel asinglepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity
AT correaburrowspaulina singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity
AT matamorosmariela singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity
AT detorovaleria singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity
AT zepedadiego singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity
AT arriazamarta singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity
AT burrowsraquel singlepointinsulinsensitivityestimatorspiseof54isagoodpredictorofbothmetabolicsyndromeandinsulinresistanceinadolescentswithobesity